

FREQ.V - FREQUENCY EXCHANGE ANNOUNCES PRIVATE PLACEMENT

For Immediate Release

VANCOUVER, BRITISH COLUMBIA – July 21st, 2025 – Frequency Exchange Corp. (“Frequency Exchange” or the “Company”) (**TSXV: FREQ, OTC: FRECF**) is pleased to announce a private placement of up to 6,000,000 units (the “Units”) at a price of \$0.25 per Unit for gross proceeds of up to \$1,500,000 (the “Private Placement”). Each Unit is comprised of one common share and one common share purchase warrant (the “Warrant”) having an exercise price of \$0.40 per Warrant and a term of 24 months from the date of closing of the Private Placement (“Closing Date”).

In the event that during the 24 month period following the Closing Date, the volume-weighted average trading price of the Common Shares on the TSX Ventures Exchange is at least \$0.70 per Common Share for any period of 10 consecutive trading days, the Company may, at its sole option, accelerate the expiry date of Warrants to the date that is not less than twenty-one (21) days following the date upon which notice of the accelerated expiry date is provided by the Company by way of news release.

Finders’ fees of up to 8% cash and 8% finders’ warrants, having the same terms as the Warrants, may be paid if applicable in respect of the private placement closing.

The Private Placement is subject to TSX Venture Exchange approval, and all securities issued will be subject to a four-month hold period.

The capital will be used to expand our team, cover general operating costs, provide a technology up-grade, pay down accrued debt and support marketing initiatives in both the consumer and public markets. Capital will also purchase increased inventory prompted by greater demand following the expansion of FREmedica Patented Technology rights to include all general wellness markets for wearables for humans and animals worldwide. All terms remain the same.

Stephen Davis, Chairman of Frequency Exchange Corp comments *“the funds currently being raised will advance the company on many levels. Continuing to expand our team is critical to strengthening our marketing effort in support of the rapid growth we anticipate. The expansion of these exclusive rights provides the ability to partner with other groups to combine our technology with their own or license to third parties. With this potential, and in the light of present success, having a world exclusive license will increase revenues significantly. We can now provide 1,000,000 NIKKIs every 90 to 120 days. We are poised for growth and cleared to sell in the United States, Europe, United Kingdom, Middle East, Australia and Asia.”*



About Frequency Exchange Corp.

Based in British Columbia, Canada, **Frequency Exchange Corp.** is publicly traded under the trading symbols global commercialization of “**NIKKI**”, a Wellness Technology delivering frequency-enhanced TSXV: FREQ; OTC: FRECF (www.FrequencyExchangeCorp.com). Frequency Exchange acquired FREmedica Technologies Inc. in 2022. FREmedica is now a wholly owned and operating subsidiary of Frequency Exchange Corp. FREmedica’s business is focused on the development and Wellness Programs. NIKKI means “Victor of the People,”; bringing wellness programs to all walks of life. FREmedica began with the development of a specialized Lyme support program designed to help people struggling with Lyme disease. Now FREmedica, through NIKKI, delivers Wellness Programs to assist with issues including sleep, pain, energy, immunity, and many more. NIKKI delivers Wellness Programs to restore and improve communication in the network of trillions of cells that make up the human body. Strong cell communication is essential to good health.

Health can be disrupted by physical, mental and emotional trauma. For example, poor sleep can be a symptom of pain, stress, and fatigue stemming from poor cell communication. NIKKI delivers specific frequencies into the body for the purpose of restoring proper cell function. Categories of Wellness Programs continue to grow. NIKKI Wellness Technology, combined with frequency-based Wellness Programs, is the result of years of development and experimentation with advanced bioenergetic technology. In third-party quality-of-life testing over an eight-week period, NIKKI proved to provide an unprecedented level of benefits ranging from better sleep and reduced pain to less anxiety and greater energy, with 90% of the test subjects experiencing improvement in overall wellness.

Learn more at: www.WeAreNikki.com
www.FrequencyExchangeCorp.com

For more information, please contact:

Frequency Exchange Corp.

Stephen Davis
CEO and Director
250-732-7170

FREmedica Technologies Inc.

Nicole Sullivan
President
nicole.sullivan@wearenikki.com

Cautionary Note Regarding Forward-Looking Information

Certain information contained herein constitutes “forward-looking information” under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the trading date of the Company’s common shares on the Exchange. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “will” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available under the Company’s profile on SEDAR+ at: www.sedarplus.com.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.